IR-Med Inc.
IRME · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $21 | $17 | $10 | $5 |
| Gross Profit | -$21 | -$17 | -$10 | -$5 |
| % Margin | – | – | – | – |
| R&D Expenses | $710 | $2,061 | $1,885 | $1,419 |
| G&A Expenses | $1,011 | $2,028 | $1,983 | $1,294 |
| SG&A Expenses | $1,231 | $2,850 | $2,742 | $2,182 |
| Sales & Mktg Exp. | $220 | $822 | $759 | $888 |
| Other Operating Expenses | $0 | -$9,822 | $135 | $74 |
| Operating Expenses | $1,941 | $4,894 | $4,762 | $3,675 |
| Operating Income | -$1,941 | -$4,911 | -$4,762 | -$3,675 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $42 | $2 | $28 | -$41 |
| Pre-Tax Income | -$1,899 | -$4,909 | -$4,734 | -$3,716 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,899 | -$4,909 | -$9,462 | -$3,721 |
| % Margin | – | – | – | – |
| EPS | -0.027 | -0.071 | -0.14 | -0.059 |
| % Growth | 62% | 49.5% | -137.3% | – |
| EPS Diluted | -0.027 | -0.071 | -0.14 | -0.059 |
| Weighted Avg Shares Out | 70,474 | 69,404 | 67,578 | 63,111 |
| Weighted Avg Shares Out Dil | 70,474 | 69,404 | 67,578 | 63,111 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3 | $0 | $6 | $5 |
| Depreciation & Amortization | $21 | $17 | $10 | $5 |
| EBITDA | -$1,875 | -$4,892 | -$4,752 | -$3,670 |
| % Margin | – | – | – | – |